CB
Centile Bioscience Inc.
SEC filingOther Technology · Bethesda, MD
Amount raised$3.1Msold at filing
Total offering$4.1M$1M still open
Investors in the raise3count reported to the SEC
FiledApr 16, 2026first sale Mar 20, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Hannah Keith MamuszkaDirector
Jakob SeidlitzExecutive Officer, Director
Richard BethlehemExecutive Officer
L. Keith MullinsDirector
Joshua BernstockExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.